Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
about
HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physiciansLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaNovel directions in HIV-1 vaccines revealed from clinical trialsSpecificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPredictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trialTowards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study.Comparison of Major and Minor Viral SNPs Identified through Single Template Sequencing and Pyrosequencing in Acute HIV-1 Infection.An HIV Vaccine for South-East Asia-Opportunities and Challenges.Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in UgandaOpportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis.Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection.The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301).HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneHigh HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda.In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalitiesMalaria diagnostics in clinical trials.Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.Recommendation of HIV test brings diagnostic dilemma home.First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
P2860
Q28082836-8CA6C778-2037-4138-8325-2BD1D8C38BDAQ28654629-921D9229-3742-4CEB-9978-463DFA0182DBQ33645528-F1CBBC4F-B17F-4809-9AAA-C100FB4AC71BQ33813145-E8E6663D-CEB8-4A6E-9A2E-40B35474D689Q33999615-8886AF53-11D3-4DC3-9527-8321A08A2273Q34663554-CB77AFAD-0F65-4397-8C6F-2D3E159CBF0AQ35752023-54645AB0-EAF8-4158-9D27-06A0F86FD842Q35759184-874ABB3C-EBEF-4E71-A463-3BE91395B15CQ35826681-92262D5A-E3F8-4438-A9A2-B48B40B890BFQ35863340-B40230FB-CE5A-4433-9627-BA6DCFF106A3Q35907384-055D284B-9BAF-452B-93CA-E958145F03CAQ36106653-5F03FC48-48E3-408B-9648-51D60936F1D6Q36226878-A2C65FD5-AE3B-435C-B22D-F683682DBDF9Q36464748-4F42EF9C-936D-49A7-B6E6-692376DB9AFCQ36931790-6565B899-C1E3-4F5E-84B5-CF37CE1CB1BEQ37039342-6323A1BC-69FD-4F59-93A6-A0F2A614DF26Q37258303-AEE0F46E-DB1E-4E5C-922A-59182FD94198Q37287631-38ED2052-9EA9-41F7-9773-C26A03A8DEE8Q37643303-834B0250-8510-4F5A-87D3-02A693954DBBQ50576393-BDE33388-E88E-41A4-A389-64C464C5589AQ52580309-040D450F-07F4-469B-840D-13A673A939DC
P2860
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@ast
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@en
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@nl
type
label
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@ast
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@en
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@nl
prefLabel
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@ast
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@en
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@nl
P2093
P2860
P3181
P356
P1476
Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients
@en
P2093
Barbara Metch
Cristine J Cooper
Joan Dragavon
Robert W Coombs
P2860
P304
P3181
P356
10.1001/JAMA.2010.926
P407
P577
2010-07-21T00:00:00Z